Data on synthesis and structure-activity relationships of tetrazolato-bridged dinuclear platinum(II) complexes

Seiji Komeda; Hiroki Yoneyama; Masako Uemura; Takahiro Tsuchiya; Miyuu Hoshiyama; Tomoya Sakazaki; Keiichi Hiramoto; Shinya Harusawa

doi:10.1016/j.dib.2021.107697

Data on synthesis and structure-activity relationships of tetrazolato-bridged dinuclear platinum(II) complexes

Data Brief. 2021 Dec 10:40:107697. doi: 10.1016/j.dib.2021.107697. eCollection 2022 Feb.

Authors

Seiji Komeda¹, Hiroki Yoneyama², Masako Uemura¹, Takahiro Tsuchiya¹, Miyuu Hoshiyama¹, Tomoya Sakazaki¹, Keiichi Hiramoto¹, Shinya Harusawa²

Affiliations

¹ Faculty of Pharmaceutical Sciences, Suzuka University of Medical Science, Suzuka, Mie 513-8670, Japan.
² Department of Pharmaceutical Organic Chemistry, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka 569-1094, Japan.

Abstract

In this data file, the synthetic procedures for the preparation of a series of anticancer tetrazolato-bridged dinuclear platinum(II) complexes ([{cis-Pt(NH₃)₂}₂(μ-OH)(μ-5-R-tetrazolato-N2,N3)]ⁿ⁺ (n = 1 or 2, tetrazolato-bridged complexes)) and of the bridging ligands of 5-substituted 1H-tetrazoles (5-R-1H-tetrazoles) are described. These compounds were characterized by ¹H-, ¹³C-, ¹⁹F- and ¹⁹⁵Pt-NMR spectroscopy and mass spectrometry.

Keywords: Cancer; MS; NMR; Platinum; Tetrazole.